Functional lipidomics in patients on home parenteral nutrition: Effect of lipid emulsions

Table 2 Fatty acid profile of the intravenous lipid emulsions and of the red blood cell membrane in the study groups

Fatty acids, % total FAs	OO-IVLE	SMOF-IVLE	OO-IVLE group	SMOF-IVLE group	No-IVLE group	HC group	P value
Palmitic (16:0)	12.8	14.1	26.2 (23.1-30.6)	28.1 (24.8-30.6)	28.1 (26.1-29.4)	26.6 (20.3-29.6)	0.040
Stearic (18:0)	3.7	4.4	16.7 (14.3-18.3)	16.8 (15.9-18.3)	16.1 (14.2-16.7)	18.1 (13.4-20.7)	< 0.001
Palmitoleic (16:1)	0	0	0.5 (0.4-0.9)	0.5 (0.2-0.8)	1.0 (0.3-1.8)	0.4 (0.2-0.7)	< 0.001
Oleic (18:1; 9c)	61.8	43.3	18.9 (17.8-23.5)	18.6 (17.3-19.9)	18.9 (16.6-22.5)	17.1 (14.2-22.2)	< 0.001
Vaccenic (18:1; 11c)	2.3	2.5	1.9 (1.6-2.7)	1.7 (1.5-2.3)	2.2 (1.7-3.3)	1.4 (0.9-2.6)	< 0.001
Linoleic (18:2; n-6)	17.7	26.9	8.7 (5.5-10.4)	9.2 (7.2-10.9)	7.7 (3.9-9.6)	11.6 (8.8-14.4)	< 0.001
DGLA (20:3; n-6)	0	0	2.2 (1.5-3.9)	1.9 (1.1-2.1)	2.2 (1.5-2.9)	2.0 (1.5-2.8)	0.049
Arachidonic (20:4; n-6)	0	0	18.3 (10.0-21.1)	12.2 (10.7-14.4)	19.2 (18.4-20.3)	16.8 (13.1-21.4)	< 0.001
Alfa-linoleic (18:3; n-3)	1.7	2.4	< 0.01	< 0.01	< 0.01	< 0.01
EPA (20:5; n-3)	0	3.4	0.6 (0.4-4.5)	3.2 (2.1-5.0)	0.5 (0.4-1.0)	0.7 (0.2-6.0)	< 0.001
DHA (22:6; n-3)	0	3	4.8 (3.4-8.4)	7.6 (6.2-10.4)	3.9 (3.0-4.7)	5.2 (2.3-8.4)	< 0.001
trans-Oleic	0	0	0.1 (0.1-0.2)	0.1 (0.0-0.2)	0.2 (0.0-0.2)	0.1 (0.0-0.2)	0.275
5-8-trans-Arachidonic	0	0	0.1 (0.1-0.2)	0.1 (0.0-0.2)	0.2 (0.0-0.1)	0.1 (0.0-0.3)	0.109
Total SFAs	16.5	18.5	43.5 (41.1-46.4)	44.9 (40.7-47.4)	44.0 (40.8-45.6)	44.3 (37.7-50.1)	0.786
Total MUFAs	65.1	45.8	21.5 (20.7-25.6)	20.9 (19.7-21.9)	21.9 (20.7-27.1)	19.5 (15.8-24.8)	0.001
Total PUFAs	19.4	35.7	34.4 (30.6-37.1)	33.7 (31.0-39.2)	33.8 (28.9-35.7)	35.7 (24.4-39.2)	0.937

The amount of each fatty acid was calculated as a percentage of the total fatty acid content (relative%). Data are expressed as medians (ranges); IVLE: Intravenous lipid emulsion; RBCs: Red blood cells; OO-IVLE: Clinoleic 20%; SMOF-IVLE: SMOF lipid ^®20%; DGLA: Dihomo-γ-linoleic acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; FAs: Fatty acids; SFAs: Saturated fatty acids; MUFAs: Monounsaturated fatty acids; PUFAs: Polyunsaturated fatty acids; n6-PUFAs: Omega 6-PUFAs; n3-PUFAs: Omega 3-PUFAs; OO-IVLE group: Patients receiving a PN admixture containing Clinoleic 20%; SMOF-IVLE group: Patients receiving a PN admixture containing SMOF lipid ^®20%; No-IVLE group: Patients receiving PN without IVLE; HC group: Healthy controls.